New hope for tough breast cancer: drug cocktail shrinks tumors before surgery
NCT ID NCT02593175
First seen Nov 06, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This study tested a combination of three drugs (panitumumab, carboplatin, and paclitaxel) given before surgery to women with triple-negative breast cancer that did not respond to standard chemotherapy. The goal was to shrink tumors enough to allow less extensive surgery. The trial included 43 participants with early-stage breast cancer. Results focused on how much cancer remained at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIA BREAST CANCER AJCC V6 AND V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.